Searchable abstracts of presentations at key conferences on calcified tissues

ba0003oc5.3 | Important pathways in bone biology and cancer | ECTS2014

Beta haemoglobin (hbb) is a novel marker of breast cancer progression

Capulli Mattia , Angelucci Adriano , Teti Anna , Sanita Patrizia , Ventura Luca , Rucci Nadia

Breast cancer (BrCa) patients with metastases restricted to bone (BO) show a longer overall survival compared to BrCa patients developing bone and visceral metastases (BV). To unveil the molecular mechanisms that segregate these two BrCa patient groups, we performed microarray analyses on bone metastasis samples from BO and BV patients, finding in the latter a set of up-regulated genes involved in oxygen metabolism. We focused on Hemoglobin B (HBB) and evaluated its expression...

ba0005p293 | Osteoporosis: evaluation and imaging | ECTS2016

DXA in clinical practice: invest in quality to improve accuracy and clinical relevance

Cagnoni Carlo , Gandolfi Stefano , Bibbo Patrizia , Iofrida Mariana , Occhipinti Maria

Introduction: Dual X-ray Absorptiometry (DXA) is currently the best technique available to evaluate bone mass, enabling the diagnosis of osteoporosis, the prediction of fracture risk and monitoring.Clinical good practices consider as preferred measuring sites the lumbar (L1–L4) and proximal femur (neck and total). The vertebral morphometry is a quantitative method for the diagnosis of vertebral fractures based on measuring vertebral heights.<p...

ba0001pp118 | Calciotropic and phosphotropic hormones and mineral metabolism | ECTS2013

Role of estrogen replacement therapy in the control of immune system in postmenopausal osteoporosis

D'Amelio Patrizia , Sassi Francesca , Buondonno Ilaria , Fornelli Giorgia , Bonardo Elena , Isaia Giovanni Carlo

Introduction: We have recently shown that T cells play a key role in postmenopausal bone loss, here we investigate the influence of estrogen replacement therapy in the control of the immune system and osteoclastogenesis.Description of methods: We enrolled in the study 30 women with postmenopausal osteoporosis randomized to estrogen replacement therapy (HRT) or raloxifene (RLX) associated with calcium and vitamin D or calcium and vitamin D alone.<p cl...

ba0003pp305 | Osteoporosis: treatment | ECTS2014

Treatment with PTH 1--84 influences glucose metabolism trough undercarboxylated osteocalcin

D'Amelio Patrizia , Spertino Elena , Sassi Francesca , Buondonno Ilaria , Tamone Cristina , Piano Simonetta , Isaia Giovanni Carlo

In the recent years the role of the skeleton in glucose and energy homeostasis has been studied. In particular the osteoblast-specific protein osteocalcin (OC), in its undercarboxylated form (uOC) has been shown to influence glucose homeostasis in animal models.The aim of our study is to evaluate if the intermittent administration of 1–84 PTH could influence glucose metabolism through its anabolic action on the skeleton.We enr...

ba0003pp353 | Osteoporosis: treatment | ECTS2014

PTH treatment induces WNT10b expression in humans lymphoid cells

Patrizia D'Amelio , Sassi Francesca , Buondonno Ilaria , Spertino Elena , D'Amico Lucia , Roato Ilaria , Isaia Giovanni Carlo

Intermittent PTH reduces vertebral fractures risk in osteoporotic patients. The mechanisms trough which PTH acts are not completely understood, it has been observed to activate Wnt pathways in osteoblasts (OBs). Activation of this pathway induces OB proliferation, differentiation and prevents apoptosis. Recently increased expression of Wnt10b by T cells during intermittent PTH, and no increase during continuous PTH has been demonstrated in mice.In order to evaluate if PTH incr...

ba0005p4 | Arthritis and other joint diseases: translational and clinical | ECTS2016

Immune system and bone cells in early rheumatoid arthritis

Buondonno Ilaria , Sassi Francesca , Rigoni Micol , Rovera Guido , Isaia Giovanni Carlo , D'Amelio Patrizia

Rheumatoid arthritis (RA) is an immune-mediated disease characterized by T cells activation and bone erosions that severely reduces patients quality of life; however a clear role for different T helper (Th) cells has not been established yet.This work aims to evaluate Th phenotypes, osteoclast (OCs) precursors cells and cytokines in peripheral blood of women affected by early RA (eRA) compared to healthy women matched for age. The study was approved by o...

ba0001pp404 | Osteoporosis: treatment | ECTS2013

Sequential therapy after PTH 1–84 treatment: comparison among bisphosphonates and strontium ranelate

Pastore Renato , Mentuccia Daniela , Pasqualetti Patrizio , Frajese Gaetano

Introduction: Evidence in literature shows how is useful to use antiresorptive drugs such as bisphosphonates, in severe osteoporosi severe after PTH (1–34 or 1–84) treatment.Methods: This study was divided into two parts: the first one analyzed BMD changes by DXA at the lumbar and femoral and serum osteocalcin and β-CTX, monitoring their performance after 6, 12 and 18 months in 71 women with severe postmenopausal osteoporosis, treated for ...

ba0003pp334 | Osteoporosis: treatment | ECTS2014

Comparison of efficacy teriparatide between denosumab and on hip BMD in women with severe post-menopausal osteoporosis

Pastore Renato , Mentuccia Daniela , Pasqualetti Patrizio , Frontoni Simona

Introduction: Teriparatide is a potent anabolic drug that has demonstrated efficacy on fracture risk reduction in women with severe postmenopausal osteoporosis. Denosumab, designed to inhibit RANKL (RANK ligand), is a fully human MAB for the treatment of osteoporosis. BMD changes, measured by DXA, is an established tool for monitoring the effects of anti-osteoporotic therapy. Our purpose is to compare teriparatide vs denosumab efficacy on hip BMD variations, in postmenopausal ...

ba0003pp346 | Osteoporosis: treatment | ECTS2014

Efficacy of Denosumab on bone metabolism after a 12-month treatment, in women with severe post-menopausal osteoporosis

Pastore Renato , Pasqualetti Patrizio , Chioma Laura , Vancieri Giuseppe , Frontoni Simona

Introduction: Denosumab, a fully human monoclonal antibody to RANK ligand, effectively reduces bone resorption by inhibiting RANK-L binding to RANK. We aimed to evaluate the efficacy of denosumab in post-menopausal women, by monitoring the evolution of different parameters of bone health: T-score, morphometry, osteocalcin and β-Ctx.Methods: A 34 women with severe postmenopausal osteoporosis, characterized by multiple vertebral fractures wer...